The short answer: nothing changed in Canada. In July 2026 a US Food and Drug Administration advisory panel voted to recommend six peptides for the list American pharmacies can compound from. The FDA has no say over Canadian law, and Health Canada still treats these peptides as unauthorized prescription drugs.
What the vote does change is the conversation, and a lot of Canadian readers are hearing about it secondhand. So here's what was decided, what wasn't, and what Health Canada's own pages say.
Status as of October 25, 2026: the FDA panel's recommendation is advisory. FDA has not added any of the six to its compounding list, and no Health Canada rule has changed because of the vote. This explains published rules. It isn't legal or medical advice.
Updated October 25, 2026: rewritten from the July 24 email; the original listed four compounds, the final vote was six.
Want the short version of what's actually approved, legal and tested? Get the free BHN cheat sheet.
What did the FDA panel vote on?
The panel voted to recommend six peptides for the 503A bulks list, the list of ingredients US compounding pharmacies may use. One failed.
The Pharmacy Compounding Advisory Committee met July 23 and 24, 2026. The tallies, as reported by DLA Piper:
BPC-157, KPV, TB-500 and MOTS-c: 8 to 6, with 1 abstention
Epitalon: 7 to 4
Semax: 8 to 5
Emideltide (DSIP): failed, 6 to 7 (STAT, Jul 24, 2026)
The July 24 email this page replaces listed only the first four. The final count was six.
The votes don't bind FDA. Before anything is added, FDA has to review the recommendation, propose a rule, take public comments and issue a final rule (DLA Piper, same source). The full US picture is in what the FDA panel vote actually means.
Does the FDA vote apply in Canada?
No. FDA decisions are US law. Canada regulates drugs under its own Food and Drugs Act, through Health Canada federally and pharmacy regulators in each province and territory.
That sounds obvious, but the vote gets shared online as "BPC-157 got approved," and that headline travels north without the fine print. Nothing was approved, even in the US. And a US list of compounding ingredients has no legal effect on what a Canadian pharmacy may do.
Are peptides legal in Canada?
Not when they're sold without Health Canada authorization. In an April 2026 advisory, Health Canada said "In Canada, peptides are generally regulated as prescription drugs" and "Unauthorized drug products are illegal in Canada" (Health Canada, Apr 9, 2026).
The same advisory names specific products. Five of the six peptides from the FDA vote are on it by name: BPC-157, KPV, TB-500, MOTS-C and Epitalon. DSIP, the one that failed the vote, is there too. Semax isn't named, but the advisory adds that "many other unauthorized peptide drugs exist."
It also says prescription drugs "should only be purchased from a licensed pharmacy," and tells people to look for an eight-digit Drug Identification Number (DIN) on the label.
Does "research use only" change that in Canada?
No. Health Canada addressed the label directly: "This type of labelling does not make these products legal or exempt from regulatory requirements" (Health Canada, Apr 9, 2026). FDA has taken the same line in the US, which is the subject of the state boards post and others.
Can a Canadian pharmacy compound these peptides?
No Health Canada page we found allows it, and the policy that governs compounding sets a bar these peptides would have trouble meeting.
That policy is POL-0051, Health Canada's Policy on Manufacturing and Compounding Drug Products in Canada. It says:
Compounding is "regulated by the respective regulatory authorities in each province/territory." Manufacturing is regulated federally.
A pharmacist has to show "a patient-healthcare professional relationship exists," and compounding should only happen "if there is a therapeutic need or lack of product availability."
The active ingredient should be an authorized drug, an ingredient "used in an authorized drug for use in Canada," or one "listed in a recognized Pharmacopoeia."
Health Canada repeated that last test to provincial regulators in a June 2025 letter about compounded GLP-1 drugs, adding that compounding "must not be used to bypass the federal drug review and approval system" (Health Canada, Jun 2, 2025). The same letter said Health Canada "is taking compliance and enforcement action" when it considers pharmacy work to be manufacturing.
Provincial colleges also apply national compounding standards written by NAPRA, the national association of pharmacy regulators. They take effect province by province as each regulator adopts them (College of Pharmacists of BC).
Our read, labeled as such: Health Canada calls five of the six "unauthorized" by name, and POL-0051 ties compounding to authorized or pharmacopoeia-listed ingredients. We didn't confirm the pharmacopoeia status of each peptide, so we're not saying no provincial pharmacy anywhere could ever do it. We are saying the US vote doesn't open any Canadian route.
Can you import peptides into Canada for personal use?
Generally no. Health Canada's personal-import guidance says "Generally, residents of Canada are not allowed to bring prescription drugs into Canada," and "This includes whether you carry them across the border or have them delivered by mail or courier." Products that fail inspection "will be refused entry or seized" (Health Canada GUI-0116).
The April advisory adds that Health Canada is working "with the Canada Border Services Agency to stop unauthorized shipments." There's more on what happens to a stopped parcel, in Canada and three other countries, in what customs actually does with a peptide order.
US vs Canada, side by side
United States | Canada | |
|---|---|---|
Who regulates | FDA; state boards regulate pharmacies and providers | Health Canada; provincial and territorial pharmacy regulators oversee compounding |
What the July vote changed | A recommendation only. FDA still has to propose and finalize a rule | Nothing. FDA decisions have no legal effect in Canada |
Compounding route for the six | Only if FDA adds them to the 503A bulks list by rule | POL-0051: patient relationship, therapeutic need, and an authorized or pharmacopoeia-listed ingredient |
Personal import | Illegal in most circumstances for unapproved drugs | Residents "are not allowed to bring prescription drugs into Canada," by mail or in person |
Enforcement on record | Warning letters to online peptide sellers | Apr 2026 advisory; permanent injunction against an online peptide seller, Jun 2026 |
Sources: DLA Piper; FDA; Health Canada advisory (Apr 9, 2026), POL-0051, GUI-0116, injunction release (Jul 29, 2026).
Is Health Canada enforcing this?
Yes, against sellers. On June 11, 2026, the Superior Court of Québec granted Health Canada a permanent injunction against an online seller of "unauthorized injectable peptides." Health Canada said that if the order isn't followed, it could pursue "referring the matter for prosecution or filing an application for contempt" (Health Canada, Jul 29, 2026).
What to watch
Two things could make the US vote matter more in Canada over time, and neither has happened yet.
FDA actually adding the six. If that happens, US pharmacies get a legal route and US data on compounded versions starts to exist. Track it on the peptide compounding status tracker.
A Health Canada statement on any of the six. So far, the April advisory is the most direct thing Health Canada has published, and it points the other way.
Until either happens, the honest summary for Canada is the same as it was before July: FDA voted, Health Canada didn't.
Want the one-page version of what's approved, what's legal and what's actually been tested? Get the free BHN cheat sheet.
Reading this from Canada? Reply and tell me which of these questions you've actually run into, and I'll keep this page current.